Piramal Pharma’s Pharma Solutions business, a contract development and manufacturing organization) recently held a grand-opening ceremony to mark the inauguration of its new active pharmaceutical ingredient (API) plant. The facility is situated at the company’s facility in Aurora, Ontario.
In addition to company leadership, the grand opening welcomed several local dignitaries and officials, including Aurora mayor Tom Mrakas, town councilors Sandra Humfryes and Rachel Gilliland; Lisa Hausz, manager of economic development and policy, and Seanna Murray of the Aurora Chamber of Commerce.
The new plant was built as part of a CAD $30m capital investment in the Aurora site. The added feature includes more than 10,000 square feet of new manufacturing space and includes two new reactor suites with additional filtration and drying capabilities.
According to the company, the API plant will support ongoing customer demand for Piramal Pharma Solutions' expertise in APIs and enhances and expands the company's ability to produce clinical to commercial scale APIs, including highly potent APIs requiring an Occupational Exposure Limit (OEL) of 1mcg/m3.
CEO Peter DeYoung said, "This new plant is just the latest in a series of expansions and capability upgrades at Aurora, with more to follow. I thank the local government for their support. In partnership with them, the team at Aurora has done commendable work in getting this facility engineered and online.”
DeYoung added, “It's evidence of our commitment to the global API market and the long-term growth of PPS as an organization. Our ultimate objective is to help customers get medicines to patients, and Aurora is an important part of that process. What's been accomplished to date in Aurora is indeed a source of pride for all of us, and we look forward to what's yet to come."
Mayor Mrakas commented, "The opening of this plant is an exciting moment for the town of Aurora. It validates our strong partnership with Piramal and affirms that we are fully supportive of their efforts to expand their presence and their capabilities. I congratulate them on this outstanding achievement. Piramal is an example of an extraordinary corporate citizen, and I'm proud of what our two strong teams have achieved by working together."
Piramal Pharma Solutions offers end-to-end development and manufacturing solutions across the drug life cycle. The company operates a globally integrated network of facilities in North America, Europe, and Asia, with services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms.
